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ic presentation can be broad, even in patients with identical 
genetic alterations. Furthermore, patients with different ge-
netic etiologies can have seemingly similar clinical presenta-
tions, such as in Dravet syndrome. While most patients carry 
mutations in  SCN1A , similar phenotypes can be seen in pa-
tients with mutations in  PCDH19 ,  CHD2 ,  SCN8A , or in rare cas-
es  GABRA1 and  STXBP1 . In addition to the genotypic and phe-
notypic heterogeneity, both benign phenotypes and severe 
encephalopathies have been recognized in an increasing 
number of genetic epilepsies, raising the question whether 
these conditions represent a fluid continuum or distinct en-
tities.  © 2016 S. Karger AG, Basel 
 Overview of the Epileptic Encephalopathies 
 Epilepsies are amongst the most common neurologi-
cal disorders affecting 5–8/1,000 individuals worldwide 
[Banerjee et al., 2009]. Up to one-third of epilepsies are 
refractory to medical treatment, and a significant propor-
tion of childhood intractable epilepsies have significant 
neurodevelopmental comorbidities, such as develop-
mental delay, plateauing, or regression. These conditions, 
in which the epileptiform abnormalities are thought to 
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 Abstract 
 Epileptic encephalopathies are severe often intractable sei-
zure disorders where epileptiform abnormalities contribute 
to a progressive disturbance in brain function. Often, epilep-
tic encephalopathies start in childhood and are accompa-
nied by developmental delay and various neurological and 
non-neurological comorbidities. In recent years, this con-
cept has become virtually synonymous with a group of se-
vere childhood epilepsies including West syndrome, Len-
nox-Gastaut syndrome, Dravet syndrome, and several other 
severe childhood epilepsies for which genetic factors are in-
creasingly recognized. In the last 5 years, the field has seen a 
virtual explosion of gene discovery, raising the number of 
bona fide genes and possible candidate genes for epileptic 
encephalopathies to more than 70 genes, explaining 20–
25% of all cases with severe early-onset epilepsies that had 
otherwise no identifiable causes. This review will focus on 
the phenotypic variability as a characteristic aspect of ge-
netic epilepsies. For many genetic epilepsies, the phenotyp-
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significantly contribute to the overall brain disturbance, 
are referred to as epileptic encephalopathies. This term is 
widely accepted by the epilepsy community to encompass 
a range of clinical syndromes characterized by severe ep-
ilepsies of childhood ( fig. 1 ).
 From Idiopathic West Syndrome to Genetic Epileptic 
Encephalopathies 
 Classically, the term epileptic encephalopathy has 
been used for epilepsy syndromes such as West syndrome 
with its classical triad of infantile spasms, hypsarrhyth-
mia, and developmental regression. As a fraction of chil-
dren with infantile spasms have prior normal develop-
ment, regress during the period of active epilepsy and re-
cover upon receiving antiepileptic medication, this pre-
sentation of West syndrome is the paradigmatic example 
of an epileptic encephalopathy.
 However, in most patients with severe epilepsy and 
in most genetic epilepsies, distinguishing between the 
contributions of the epileptic abnormality and of the un-
derlying disease is difficult [Guerrini, 2006]. For exam-
ple, in  CDKL5 encephalopathy, one of the most com-
mon causes of infantile spasms, most patients also have 
prior developmental delay [Archer et al., 2006]. How-
ever, the contribution of the often intractable epileptic 
activity to the overall developmental outcome in those 
patients is not fully clear. In other conditions such as 
Dravet syndrome due to mutation in  SCN1A, develop-
mental plateauing is frequently observed in the second 
year of life [Harkin et al., 2007]. Again, the developmen-
tal trajectory often appears unrelated to the overall sei-
zure burden, and the epileptiform activity in patients 
with Dravet syndrome is not as prominent and continu-
ous as seen in other epileptic encephalopathies [Nab-
bout et al., 2013]. In both conditions, the underlying ge-
netic etiology seems to independently drive both the 
neurodevelopmental and epilepsy phenotypes rather 
than causing excessive epileptic activity, which can then 
lead to secondary neurodevelopmental comorbidities. 
While the precise contribution of the seizure burden to 
the neurodevelopmental comorbidities is difficult to 
quantify, both conditions are conceptually referred to as 
epileptic encephalopathies, given that the epilepsy phe-
notype is a prominent feature of the disease and is the 
primary treatment target.
 In addition, when considering the genetic aspects of 
childhood epilepsy, the concept of idiopathic West syn-
drome may be of limited clinical value. While a genetic 
etiology in severe epilepsies can be securely implicated in 
up to one-third of patients, this does not apply to patients 
 Fig. 1. Age distribution of various epileptic encephalopathies. ABPE = Atypical benign partial epilepsy; ESES = 
electrical status epilepticus in sleep; FIRES = febrile infection-related epilepsy syndrome; LKS = Landau-Kleffner 






with idiopathic self-resolving West syndrome. In these 
patients, no genetic etiology has been identified to date. 
The lack of gene discovery in patients with idiopathic self-
resolving epilepsy can be attributed to at least 2 factors: 
the lack of inclusion of these patients in published gene 
discovery studies, and the fact that other genetic inheri-
tance models such as dominant inheritance with incom-
plete penetrance may potentially be involved, which 
makes gene discovery more challenging. This suggests 
that while we borrow the concept of epileptic encepha-
lopathy from patients where the contribution of the ab-
normal epileptic activity can be clearly delineated, there 
is little evidence to date that these condition share similar 
underlying causes and pathophysiology.
 In summary, the epilepsy community applies the 
concept of epileptic encephalopathy to a heterogeneous 
group of severe disorders, which have epilepsy and EEG 
findings as prominent features of the disease. However, 
for most known genetic epileptic encephalopathies, 
neurodevelopmental comorbidities are a primary fea-
ture of the genetic disease rather than secondary to the 
temporary disturbance of brain function as a result of 
excessive epileptiform activity. This concept has helped 
raise awareness for this group of disorders and has al-
lowed for joint cohort studies to probe the underlying 
genetic etiology [EuroEPINOMICS-RES Consortium et 
al., 2014].
 Given this conceptual overlap with genetic disorders 
primarily associated with neurodevelopmental condi-
tions such as intellectual disability or autism, these condi-
tions have shared genetic etiologies. This overlap is par-
tially due to the heterogeneous clinical presentations of 
some of the genetic alterations. In addition, some of the 
overlap is due to ascertainment bias, depending on which 
phenotypic feature was initially the driving force behind 
the diagnostic work-up. For example, it can be assumed 
that many patients with intellectual disability due to mu-
tations in  SCN1A have a variant of Dravet syndrome 
[Harkin et al., 2007]. Within an increasing understanding 
of causative genes and their associated phenotypic fea-
tures, the true differences between primary genetic neu-
rodevelopmental disorders and primary genetic epileptic 
encephalopathies is slowly emerging [Epi4K Consortium 
et al., 2013].
 Fig. 2. Timeline of gene discovery in human epilepsies. 





 History of Gene Discovery in Epileptic 
Encephalopathies 
 The history of gene discovery in epileptic encephalop-
athies is intertwined with the overall dynamics of gene 
discovery in epilepsies in general, which occurred largely 
in 3 stages: a stage of gene discovery in familial epilepsies, 
a period of relative stagnation, and the current era of mas-
sive parallel sequencing that was ushered in by large-scale 
studies for copy number variants ( fig. 2 ; table 1).
 Lessons from the Era of Family Studies 
 During the initial era of family studies, many genes 
underlying relatively mild dominantly inherited familial 
epilepsies had been discovered including  SCN1A ,  SCN1B , 
 KCNQ2 ,  KCNQ3 , and  GABRG2  [Steinlein, 2004]. While 
these gene discoveries initially had no direct link to the 
more severe epileptic encephalopathies, they laid the gen-
eral pathophysiological concept, such as the channelopa-
thy concept of the human epilepsies [Steinlein, 2004], 
which eventually provided the backdrop for the more re-
cent gene discoveries. In addition, the familial epilepsy 
genes discovered in the early 2000s have frequently been 
rediscovered in more severe phenotypes [Claes et al., 
2003; Patino et al., 2009; Weckhuysen et al., 2012; Carvill 
et al., 2013, 2014], adding to the impression that many 
genes implicated in human epilepsies can result in a range 
of different epilepsy phenotypes, from mild to severe clin-
ical presentations.
 One major gene for epileptic encephalopathies that 
emerged from the era of family studies was the  ARX 
gene [Strømme et al., 2002]; a gene initially identified in 
families with X-linked mental retardation and epilepsy. 
 ARX , coding for the X chromosome-linked Aristaless-
related homeobox gene, was found as the causative gene 
in a range of X-linked conditions including lissenceph-
aly, agenesis of the corpus callosum with abnormal gen-
italia, syndromic and nonsyndromic intellectual dis-
ability, and infantile spasms without brain malforma-
tion. Even though  ARX has been a major candidate gene 
for refractory epileptic encephalopathies, the overall 
proportions of genetic epilepsy that can be attributed to 
 ARX is probably relatively small. However, as the  ARX 
genetic alteration that is mainly associated with infan-
tile spasms is a polyalanine expansion [Strømme et al., 
2002], it is typically not detected by next-generation se-
quencing. Therefore, the true frequency may be under-
reported.
 The Era of Candidate Studies – Identifying the 
Classical Genes for Epileptic Encephalopathies 
 While human epilepsy gene discovery slowly stagnat-
ed at the turn of the millennium, candidate gene research 
and studies detecting genetic alterations based on unusu-
al genetic recombination events were able to identify 
some of the most common genes for human epilepsies, 
namely  SCN1A in Dravet syndrome and  CDKL5 in a vari-
ant Rett syndrome [Escayg et al., 2000; Weaving et al., 
2004]. Both strategies took advantage of the technology 
that was available at the time before systematic genome-
wide screens for structural rearrangements through ge-
nome-wide microarrays or next-generation sequencing 
technologies became feasible.  SCN1A in Dravet syn-
drome was identified through a candidate gene sequenc-
ing approach in severe fever-related epileptic encepha-
lopathy patients [Escayg et al., 2000]. This was based on 
the observation that milder forms of familial fever-asso-
ciated epilepsies had previously been implicated in ge-
netic epilepsy with febrile seizures plus (GEFS+) where 
mutations in  SCN1A have been identified [Escayg and 
Goldin, 2010]. While candidate gene studies in the field 
of epilepsy were usually underpowered and unable to se-
curely implicate a given gene due to the underlying het-
erogeneous architecture of the human epilepsies, the dis-
covery of  SCN1A in Dravet syndrome was exceptional. 
There is an unusually strong genotype-phenotype corre-
lation between  SCN1A and Dravet syndrome, and the fre-
quency of this subtype of epileptic encephalopathies has 
been much higher than initially expected. By 2016, it is 
assumed that Dravet syndrome has a population frequen-
cy of 1: 22,000 [Bayat et al., 2015], suggesting that this syn-
drome alone accounts for a significant proportion of epi-
leptic encephalopathies. The  CDKL5 gene was identified 
through sequencing of the breakpoints of a balanced de 
novo translocation [Kalscheuer et al., 2003] in 2 female 
patients with severe intellectual disability and infantile 
spasms. In retrospect, in the era of candidate gene studies, 
both findings were unusually successful taking advantage 
of low-hanging fruits, given the very strong genotype-
phenotype correlation in  SCN1A and a unique recombi-
nation event in  CDKL5 .
 The Era of Genome-Wide Studies – from Microarrays 
to Exome Sequencing 
 The era of genome-wide screening technologies 
opened up the door to many of the recent gene findings 
in epileptic encephalopathies, starting with genes identi-
fied through microdeletions and ending with an ongoing 






ing technologies (table 1). Genome-wide technologies 
have offered the possibility to screen large cohorts of pa-
tients in parallel allowing the detection of recurrent al-
terations that are still rare in a particular patient cohort. 
These technologies also offered the possibility to replace 
the strategy of candidate gene analysis by hypothesis-free 
approaches.
 The  STXBP1 gene is the prime example of genes that 
were identified in the early stages of genome-wide studies 
through systematic testing for genome-wide duplications 
and deletions in patients with severe epilepsies. After a de 
novo microdeletion spanning  STXBP1 was identified in a 
proband with Ohtahara syndrome, a severe infantile epi-
leptic encephalopathy [Saitsu et al., 2008], additional de-
letions and mutations were subsequently identified in 
other patients with early-onset epileptic encephalopa-
thies. To date,  STXBP1 is one of the most common genes 
for epileptic encephalopathies characterized by a wide 
phenotypic spectrum with infantile spasms and severe in-
tellectual disability as the main consistent features [Stam-
berger et al., 2016]. Likewise, the  GRIN2A gene, currently 
one of the most common genes for epilepsy-aphasia syn-
dromes, was initially discovered as the gene in a critical 
region of 3 patients with epileptic encephalopathies and 
overlapping microdeletions [Reutlinger et al., 2010]. The 
 CHD2 gene was discovered both through follow-up stud-
ies of identified solitary microdeletions in patients and 
through the first systematic exome studies in the field 
[Suls et al., 2013].
 With the advent of next-generation sequencing stud-
ies, the focus on gene discovery in epileptic encephalopa-
thies shifted toward systematic family-based exome se-
quencing to identify de novo mutations on an exome-
wide scale. Studies applying these technologies, most 
notably the Epi4K study [Epi4K Consortium et al., 2013], 
were able to emphasize the role of known genes and also 
to provide evidence for additional candidates. Novel 
genes such as  GABRB3 and  DNM1 were strongly linked 
to epilepsy based on the identification of statistically sig-
nificant enrichment of de novo variants in several indi-
viduals with disease ( table  2 ) [EuroEPINOMICS-RES 
Consortium et al., 2014]. Study paradigms like this have 
become increasingly relevant in the era of genomic se-
quencing, given the large-scale data produced by massive 
parallel sequencing technologies.
 Paradigm Shifts 
 Next-generation sequencing technologies have shifted 
the focus of genomic science from data generation to data 
interpretation. While genetics has traditionally been a rel-
atively resource-scarce field, the flood of genomic data 
generated by exome and genome sequencing has over-
come the prior bottleneck of limited data generation at 
the expense of a new interpretation bottleneck – simply, 
we are generating more data that we can analyze, given 
the current knowledge. With the arrival of massive 
amounts of data, novel paradigms have been established 
in the field largely reflecting a growing sense of caution of 
not overinterpreting genomic findings in the absence of 
confirmatory data or statistical association. In the ab-
sence of appropriate guidelines for variant interpretation 
and gene-disease associations in the genetics community, 
wrong assertions about genes and variants became very 
abundant in the literature, posing a major interpretation 
Table 1.  Examples of genes for epileptic encephalopathies
Gene Major epilepsy phenotype Year of discovery, reference
SCN1A Dravet syndrome Escayg et al., 2000
CDKL5 atypical Rett syndrome Kalscheuer et al., 2003
STXBP1 Ohtahara syndrome Saitsu et al., 2008
SCN2A infantile spasms Heron et al., 2002
SCN8A infantile spasms Veeramah et al., 2012
KCNT1 malignant migrating partial seizures of infancy Heron et al., 2012
KCNQ2 neonatal epileptic encephalopathy Singh et al., 1998
DNM1 infantile spasms EuroEPINOMICS-RES Consortium et al., 2014
TBC1D24 various epileptic encephalopathy phenotypes Falace et al., 2010
GABRA1 Dravet syndrome Cossette et al., 2002
GRIN2A epilepsy-aphasia syndromes Reutlinger et al., 2010
SLC6A1 myoclonic astatic epilepsy Carvill et al., 2015
CHD2 photosensitive epileptic encephalopathy Carvill et al., 2013





challenge for research and clinical laboratories. For ex-
ample, in 2016, previously implicated genes including 
 CACNA1H ,  SCN9A ,  EFHC1 ,  CLCN2 ,  GABRD , or  SRPX2 
were no longer considered causative genes after careful 
assessment of the available evidence linking those genes 
to disease ( table 2 ) [Pal and Helbig, 2015; Subaran et al., 
2015]. These examples suggest that the current wave of 
gene discovery is paralleled by a wave of  gene retirement , 
constantly refining the list of possible genetic etiologies 
based on an evolving catalogue of criteria [Richards et al., 
2015].
 Genotype-Phenotype Correlations 
 Necessity to Consider Genotype-Phenotype 
Correlations 
 Starting with the discovery of familial epilepsy syn-
dromes, the broad range of phenotypes in families has 
been puzzling. For example, in families with GEFS+ due 
to mutations in  SCN1A , a broad spectrum of phenotypes 
ranging from unaffected individuals, individuals with 
simple febrile seizures to patients with severe epileptic en-
cephalopathies can be observed [Miller and Sotero de 
Menezes, 1993; Goldberg-Stern et al., 2014]. Therefore, 
while the clinical validity of many epilepsy genes is be-
yond doubt, the factors influencing the phenotypic ex-
pression remain to be determined. Classically, the genet-
ic variation in the gene itself is examined as a first step, 
asking the question whether particular mutations or ge-
netic alteration preferentially associate with a particular 
phenotype. Such an observation has been made for a 
small subset of genetic epilepsies. For example, loss-of-
function variants such as nonsense, invariant splice site, 
or frameshift mutations in  SCN1A are primarily seen in 
patients with Dravet syndrome and rarely in milder fa-
milial cases [Guerrini et al., 2010]. Likewise, in the  ARX 
gene, polyalanine expansions have a strong association 
with infantile spasms with unremarkable MRI imaging in 
contrast to genetic alterations that result in lissencephaly 
[Strømme et al., 2002]. Furthermore, in some familial ep-
ilepsy syndromes such as benign familial epilepsies due to 
mutations in  SCN2A or  SCN8A , the milder familial cases 
are due to particular recurrent mutations [Berkovic et al., 
2004; Gardella et al., 2016]. On a larger scale, however, a 
broad phenotypic spectrum is a common feature of ge-
netic epilepsies, and key phenotypic differences can even 
be observed between individuals with the same genetic 
alteration.
 Genes with Benign and Severe Epilepsy Phenotypes 
 An emerging number of epilepsy genes are found to 
underlie both benign and severe phenotypes ( table 3 ). Al-
though  SCN1A and  SCN1B were historically the first 2 
genes known to cause GEFS+ with milder self-limited fa-
milial epilepsies, more severe phenotypes have subse-
quently been discovered [Claes et al., 2001; Patino et al., 
2009].  SCN1A is the major gene for Dravet syndrome, an 
infantile-onset fever-associated epileptic encephalopa-
thy. Homozygous variants in  SCN1B have also been found 
in patients with Dravet syndrome [Ogiwara et al., 2012]. 
Mutations in  KCNQ2 which are known to cause benign 
familial neonatal seizures [Biervert et al., 1998; Singh et 
al., 1998] have also been found in severe neonatal epilep-
tic encephalopathies, and the latter phenotype is likely to 
be much more common than the benign familial form 
[Weckhuysen et al., 2012, 2013]. Mutations in  SCN2A 
were initially identified in families with benign familial 
neonatal-infantile seizures [Berkovic et al., 2004]. Subse-
quently, de novo mutations in  SCN2A were found to be 
Table 2.  Previously implicated genes with insufficient evidence for their role in the disease
Gene Year of discovery, 
reference
Comment
EFHC1 Suzuki et al., 2004 initial variants found to be population variants
GABRD Dibbens et al., 2004 not confirmed in studies after initial discovery, no reported de novo 
mutations in epilepsy
SCN9A Singh et al., 2009 variable gene, lack of association
CLCN2 Haug et al., 2003 not confirmed in studies after initial discovery
CACNA1H Chen et al., 2003 not confirmed in studies after initial discovery, no reported de novo 
mutations in epilepsy
SRPX2 Roll et al., 2006 not confirmed in studies after initial discovery, initial families were found 






one of the most common causes of epileptic encephalop-
athies [Nakamura et al., 2013; Howell et al., 2015]. In ad-
dition to these examples where severe phenotypes were 
recognized after the initial identification of mild familial 
forms, the opposite sequence of discovery has also been 
observed for some genes including  SCL2A1 and  SCN8A .
 SLC2A1 , coding for  GLUT1 as the main glucose trans-
porter across the blood-brain barrier, was initially identi-
fied in a severe neonatal epileptic encephalopathy some-
times referred to as De Vivo syndrome [De Vivo et al., 
1991]. However, it has also become clear that mutations 
in  SCL2A1 can be found in patients with early-onset ab-
sence epilepsies and in familial epilepsies with milder fo-
cal and generalized epilepsies as a presenting feature [Suls 
et al., 2009; Mullen et al., 2010]. This observation has 
prompted many clinicians to reconsider the possibility of 
GLUT1 deficiency in patients with refractory generalized 
or focal epilepsies, given that patients with GLUT1 defi-
ciency favorably react to the ketogenic diet [De Vivo et 
al., 1991]. For  SCN8A , a further ion channel gene initially 
implicated in severe early-onset epileptic encephalopa-
thies [Veeramah et al., 2012], a recent study has identified 
a mild familial epilepsy syndrome with benign infantile 
convulsions and paroxysmal choreoathetosis due to a re-
current  SCN8A mutation, implicating yet another com-
mon epileptic encephalopathy gene in a more benign ep-
ilepsy syndrome [Gardella et al., 2016].
 For the  KCNT1 gene, a different and unusual pheno-
typic spectrum is emerging. This gene is implicated in a 
severe early-onset epileptic encephalopathy referred to as 
malignant migrating partial seizures of infancy [Barcia et 
al., 2012]. However, mutations in this gene have also been 
found in families with severe frontal lobe epilepsy [Heron 
et al., 2012]. Surprisingly, both conditions may exist in the 
same family [Møller et al., 2015]. While the clinical spec-
trum of  KCNT1 does not range from mild to severe in the 
same way as the other epilepsy genes do, this novel phe-
notypic spectrum deserves mentioning as it may provide 
a unique insight into the role and function of the caus-
ative gene.
 In summary, even though the clinical presentations of 
benign epilepsies and severe epileptic encephalopathies 
are vastly different, several genes are known to cause both 
conditions. This indicates that both severe epileptic en-
cephalopathies and familial epilepsies do not exist in iso-
lation, but that the careful examination of both ends of 
the spectrum can be mutually informative.
 Fluid Overlap versus Distinct Entities 
 Are the various entities associated with major epilepsy 
genes distinct entities or do they occur on a fluid spec-
trum ranging from benign to severe phenotypes? The ge-
netic approaches to human epilepsies have always had a 
strong ascertainment bias. While the main focus of early 
genetic studies was family studies, the current explosion 
of genetic findings is heavily biased towards severe treat-
ment-resistant epilepsies. Therefore, both the benign end 
and severe end of the putative spectrum for each gene are 
heavily overrepresented and currently provide the im-
pression that the phenotypes associated with genes such 
as  SCN1A ,  SCN2A ,  SCN8A ,  KCNQ2 , or  SCL2A1 may rep-
resent distinct entities at both ends of the spectrum rath-
er than a continuum. To address the question of the full 
phenotypic spectrum, the example of  SCN1A may be in-
structive. Given the overall frequency of  SCN1A muta-
tions in fever-associated epilepsies in general, this gene 
has frequently been tested and identified in familial cases, 
providing a comprehensive overview of the associated 
phenotypes [Miller and Sotero de Menezes, 1993; Helbig, 
2015]. The  SCN1A example shows a continuum of phe-
Table 3.  Genetic etiologies in human epilepsies with both mild and severe phenotypes
Gene Mild phenotype Severe phenotype
SCN1A genetic epilepsy with febrile seizures plus Dravet syndrome
SCN2A benign familial neonatal-infantile seizures neonatal epileptic encephalopathy
SCN8A benign familial neonatal-infantile seizures early-onset epileptic encephalopathy
KCNQ2 benign familial neonatal seizures neonatal epileptic encephalopathy
SLC2A1 familial focal epilepsy neonatal epileptic encephalopathy (De Vivo syndrome)
GABRA1 juvenile myoclonic epilepsy early-onset epileptic encephalopathy
GABRG2 genetic epilepsy with febrile seizures plus early-onset epileptic encephalopathy
GRIN2A epilepsy-aphasia syndromes early-onset epileptic encephalopathy
PRRT2 benign familial infantile seizures early-onset epileptic encephalopathy





notypes ranging from simple febrile seizures to a more 
severe epilepsy syndrome, arguing for a continuum rath-
er than mutation-specific entities that do not overlap. 
This gradient is somewhat reflected in the functional al-
terations of the various  SCN1A variants, ranging from 
mild alterations to complete loss of function [Meng et al., 
2015]. Also, common variants in  SCN1A have been found 
to be associated with various epilepsy phenotypes as com-
mon risk factors [Kasperaviciute et al., 2013; Feenstra et 
al., 2014; International League Against Epilepsy Consor-
tium on Complex Epilepsies, 2014]. With increasing ge-
netic studies in common epilepsies, the middle ground 
between the extremes of mild familial epilepsies and se-
vere epilepsy encephalopathies will be increasingly ex-
plored. It will be interesting to see to what extent the 
 SCN1A example also holds true for other genetic etiolo-
gies or whether they represent distinct entities.
 Future Directions 
 Genotypes, Phenotypes and Modifiers 
 Epileptic encephalopathies are characterized by genet-
ic and phenotypic heterogeneity. A similar epilepsy phe-
notype such as West syndrome, Lennox-Gastaut syn-
drome, or Dravet syndrome can be caused by different 
genes, and mutations in a given gene can result in various 
phenotypes. While some genes and variants allow for a 
precise genotype-phenotype correlation, the spectrum of 
phenotypes associated with a given gene is often unex-
plained and not necessarily related to a particular variant 
in that gene. Therefore, the majority of phenotypic het-
erogeneity in genetic epilepsies is unexplained, both with 
regards to the epilepsy phenotype and other neurodevel-
opmental comorbidities. For example, truncating vari-
ants in  SCN1A can result in the full clinical picture of 
Dravet syndrome including developmental plateauing re-
sulting in severe intellectual disability. However, some 
patients with truncating  SCN1A mutations and similarly 
severe epilepsies have a normal or near-normal intellect, 
even though this constellation is assumed to be very rare. 
The reason for this heterogeneity is not understood. Ge-
netic modifiers are typically implicated, but the study par-
adigms to successfully address these questions still need 
to be developed.
 Patient Registries, Natural History Studies, and 
Personalized Medicine 
 Despite a strong emphasis on epilepsy phenotypes, 
many clinical aspects of genetic epilepsies remain un-
known. The increasing interest to embark on systematic 
treatment studies for personalized medicine approaches 
in genetic epilepsies have highlighted the need to better 
elucidate the constant and variable features of genetic ep-
ilepsies and to identify ideal points for intervention. This 
has rekindled interest in the field to understand the natu-
ral history of epileptic encephalopathies and in creating 
patient registries and databases in collaboration with 
an emerging active patient community for many of the 
known epilepsy genes. 
 In summary, over the last decade, the epileptic enceph-
alopathies have made transition from disorders with a 
largely unknown etiology to a broadening group of dis-
tinct genetic entities that can be identified in up to one-
third of all patients. Phenotypic variability is an emerging 
theme for genetic epilepsies that will have a profound im-
pact on personalized medicine approaches for these con-
ditions.
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